Core Viewpoint - Foton Holdings Limited has reduced its stake in Highland Holdings (01676) by selling 9.1 million shares at an average price of HKD 0.55 per share, totaling HKD 5.005 million, resulting in a new holding of 18.38 million shares, representing 8.38% ownership [1] Summary by Category - **Share Reduction** - Foton Holdings Limited sold 9.1 million shares of Highland Holdings [1] - The average selling price was HKD 0.55 per share [1] - The total amount raised from the sale was HKD 5.005 million [1] - **Current Holdings** - After the sale, Foton Holdings Limited's remaining shares in Highland Holdings are 18.38 million [1] - The ownership percentage post-sale is 8.38% [1]

Core Viewpoint - The news highlights the positive performance of Yu Wen Group, driven by its expansion into the manhua (comic) drama sector and the upgrade of its "Creative Partner Program" [1] Company Summary - Yu Wen Group's stock rose by 5.36%, reaching HKD 44.02, with a trading volume of HKD 311 million [1] - The CEO announced the entry into the manhua drama market, in addition to its focus on short dramas [1] - As of October 2025, Yu Wen has 30 manhua works with over 10 million views, including hits like "The Son-in-law of the Ming Dynasty" and "Invincible Simulation System," with some exceeding 100 million views [1] Industry Summary - According to data from Giant Engine, the supply of manhua dramas saw a compound monthly growth rate of 83% in the first half of 2025, producing over 3,000 works and increasing revenue scale by 12 times [1] - The market size for manhua dramas is expected to exceed RMB 20 billion for the year [1] - The manhua market is currently in the growth phase 1.0, with future competition likely shifting back to content quality after initial technological advantages [1] - Analysts suggest that leading platforms and IP owners are intensifying their focus on manhua and AI video tools, which will further accelerate the growth of the AI manhua industry [1]

中国证监会经调查后认为该重组交易在公开前为内幕信息，而潘卫东不晚于2023年12月5日知悉内幕信 息。在该重组交易公开前，潘卫东利用恩必普的证券账户，于2023年12月8日至2023年12月20日期间， 累计买入石药创新2742580股，累计买入金额为人民币9998.88万元。 另外，调查中潘卫东存在躲避推脱等不配合执法人员询问等情形。证监会决定：责令潘卫东依法处理非 法持有的证券，对潘卫东处以500万元的罚款。 公告显示，上述重组交易相关工作于2024年1月10日发布停牌公告，但这笔交易最终在2025年4月28日公 告终止。对于终止的原因，新诺威称，综合考虑医药行业及资本市场整体环境等因素，并经公司与相关 各方充分沟通、审慎分析和友好协商后作出的审慎决定，不存在公司及相关方需承担相关违约责任的情 形。 11月3日，石药集团（1093.HK）发布公告称，执行董事潘卫东近日收到中国证监会向其出具《行政处 罚决定书》。 潘卫东已于2024年9月23日辞任石药创新董事长。根据决定书，潘卫东有权申请行政复议或提起行政诉 讼。石药集团表示，在公告日期，公司分别通过恩必普及另一全资附属公司石药集团欧意药业有限公司 持有新 ...

Group 1 - The company ZTO Express (02057) announced a share repurchase plan, committing to buy back 383,300 shares at a total cost of $7.0855 million [1] - The repurchase price per share is set between $18.19 and $18.63 [1]

民生证券此前指出，25H1，公司印尼业务以量补价，实现盈利0.24亿元，同比增加0.67亿元，盈利能力 提升。公司目前拥有印尼SDE、TSE、SME、VSE、IMJ五大矿区采矿权，先行开发的SDE矿区已规划 产能达3000万吨。鉴于SDE矿区开发经验，资源、审批、成本、模式优势的综合加持下，公司未来成长 空间广阔，有望成为海外项目标杆。 消息面上，11月3日，中国秦发发布公告，本公司欣然宣布，全资附属公司PT Trisula Sumber Energi(TSE)于印度尼西亚南加里曼丹的煤矿开发进度最新情况。TSE煤矿(TSE煤矿)位于印度尼西亚南 加里曼丹省哥打巴鲁县北部，地处梅拉图斯山脉东麓地带。该采矿特许区面积达168平方公里，涵盖 Kelumpang Hulu及Kelumpang Barat部分地区。TSE煤矿目前处于营运前规划阶段，尚未开始建设工程。 本公司预计将于2026年第一季度展开矿场建设活动。 中国秦发(00866)涨超6%，截至发稿，涨6.16%，报3.1港元，成交额911.63万港元。 ...

Core Viewpoint - 康诺亚-B (02162.HK) has experienced a significant increase in stock price, rising over 7% to reach 64.55 HKD, with a trading volume of 281 million HKD [1] Company Summary - 康诺亚-B's stock price increased by 7.14% [1] - The current stock price is 64.55 HKD [1] - The trading volume reached 2.81 billion HKD [1]

每经AI快讯，HSSP INTL(03626.HK)今日复牌后一度涨超50%，午后转跌且跌幅持续扩大。截至发稿， 跌11.88%，报2.82港元，成交额5327.37万港元，全天振幅达82.5%。 ...

蚂蚁押注RWA，Jovay把万亿现实资产往链上拽，这事儿说大不大，说小也不小，但够热闹且够现实， 让人不得不盯着看，下面我把这摊事儿从头到尾摆清楚，别急着评头论足，先看看发生了什么，然后你 自己体会。 10月31日，蚂蚁集团公开宣布推出基于以太坊的Layer2网络"Jovay"，并把它定为现实世界资产上链的 基础设施，时间点就这么钉死了，消息一出，行业里像撒了盐一样炸开了锅。 蚂蚁这回没走以前那套自家链的老路，他们把底层选在以太坊，技术上用的是ZK-Rollup，这意味着成 本和扩展性都要往好处走，别把这些词听得高大上，实话说就是想把大量资产搬上链，又不想被高额 Gas给掐死。 质疑也很现实，监管怎么适配链上证券这是个大命题，美国SEC和欧盟监管政策不是好商量的，蚂蚁还 要面对所谓的中心化悖论——技术上可以去信任，但出入金的通道仍掌握在少数机构手里。 还有地缘政治的风险，在中美科技脱钩的背景下，任何一家中国公司主导的全球金融基建都会被放大审 视，甚至可能遭遇限制，这并非空想，而是正在发生的事。 蚂蚁内部并不是铁板一块，他们的路线调整也有内部博弈，从自研链转向以太坊，这是战略上的大转 弯，意味着要跟全球开源生态 ...

每经编辑｜陈柯名 潘海福 11月3日，港股黄金零售品牌商集体下挫。截至发稿，老铺黄金、周大福、六福集团大跌超7%，周生生跌超6%。 | 六福集团 | 23.040 | -7.40% | 0.45% | | --- | --- | --- | --- | | HK HK0590 | | | | | 周大福 HK HK1929 | 14.060 | -7.62% - | 0.47% | | 老铺黄金 HK HK6181 | 631.000 - | -7.82% - | 1.01% | 此外，A股方面，贵金属板块领跌。截至发稿，湖南黄金跌超4%，晓程科技、山金国际跌超2%、中金黄金跌1.94%。 | 名称/代码 | 最新 ◆ · 涨幅 ◆ 5日涨幅 ◆ ▶ | | --- | --- | | 四川黄金 | 27.01 -1.10% -0.41% | | 001337 | | | 领涨龙头3 | | | 西部黄金 | 27.16 -1.24% -3.66% | | 601069 | | | 招金黄金 | 11.94 -1.49% -0.50% | | 000506 | | | 山东黄金 | 35.45 -1.64% ...

Core Viewpoint - 康诺亚-B (02162) shares rose over 7%, currently at 64.55 HKD, with a trading volume of 281 million HKD, following a bullish report from Goldman Sachs which assigned a "Buy" rating and a target price of 92.67 HKD [1] Group 1: Product Approval and Market Potential - 康诺亚's first commercial product, Stapokibart, has been approved in mainland China for atopic dermatitis, chronic sinusitis, and seasonal allergic rhinitis, establishing a first-mover advantage in these areas [1] - Goldman Sachs estimates that Stapokibart could lay the foundation for the company's valuation, with peak sales expected to exceed 5 billion RMB by 2035 [1] Group 2: Future Growth Drivers - The company anticipates significant growth from CM512, which is expected to become a preferred option for asthma and chronic obstructive pulmonary disease, with projected global sales of 3.3 billion USD before and 694 million USD after the PoS stage by 2035 [1] - In the first half of this year, Stapokibart generated sales of approximately 169 million RMB, indicating strong market performance [1] Group 3: Competitive Advantages and Strategic Plans - 华泰证券 highlighted Stapokibart's significant efficacy and safety advantages in the atopic dermatitis field, along with strong competitiveness, particularly in its exclusive indications in the nasal field, driving rapid sales growth [1] - The company plans to participate in the 2025 medical insurance negotiations, which is expected to enhance accessibility for its products [1] - Multiple early-stage pipelines show strong global potential, with several catalysts expected to materialize [1]